UPDATE: J.P. Morgan Lowers PT on WuXi PharmaTech to $17

J.P. Morgan is out with its report today on WuXi PharmaTech WX, lowering its PT from $20 to $17. In its report, J.P. Morgan writes, "Establishing 2012 PT of $17, which we believe appropriately reflects near-term uncertainties around pharma R&D allocations. We continue to believe WuXi remains well-positioned to benefit from the secular trend of outsourcing R&D to China. Based on our 2012 non-GAAP EPS projection of $1.25, shares trade at 10.3x 2012 P/E, a 22% discount to the peer group of CROs. Our December 2012 PT is based on a 14x multiple to our 2012 EPS target, in line with the peer average." J.P. Morgan Maintains Overweight on WX. Shares of WX closed Tuesday at $13.01.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsJ.P. Morgan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!